Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02161406 · ClinicalTrials.gov registry record · Phase 2

A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis

A Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, sponsored by Dinesh Khanna, MD, MS.

Completed
Registry status
Phase 2
Development phase
88
Enrollment target
20
Study locations

NCT02161406 is a Phase 2 study of Diffuse Cutaneous Systemic Sclerosis that has completed, run by Dinesh Khanna, MD, MS. The registered enrollment target is 88 participants, roughly in line with the 90-participant average among 6 other Diffuse Cutaneous Systemic Sclerosis trials with a reported enrollment target. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02161406, a Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, has completed, sponsored by Dinesh Khanna, MD, MS.

COMPLETED
Registry status
Phase 2
Development phase
88 participants
Enrollment target
20
Study locations

Study Summary

The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score \[mRSS\]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.

Conditions Studied

Diffuse Cutaneous Systemic Sclerosis

Interventions

  • DRUG Placebo
  • DRUG Abatacept

Study Locations (20)

New York

  • Steffens Scleroderma Center - Albany
  • NorthWell Health - Great Neck
  • Hospital for Special Surgery - New York
  • Columbia University - New York

California

  • Arthritis Associates of Southern California - Los Angeles
  • University of California- Los Angeles - Los Angeles
  • Stanford University - Redwood City

Massachusetts

  • Harvard Mass General - Boston
  • Boston University - Boston

Minnesota

  • University of Minnesota - Minneapolis
  • Mayo Clinic - Rochester

Ohio

  • Cleveland Clinic - Cleveland
  • Ohio State University Medical Center - Columbus

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • University of Pittsburgh - Pittsburgh

District of Columbia

  • Georgetown University - Washington D.C.

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2014-09
Est. Completion 2018-10-17
Phase Phase 2

Sponsor

Dinesh Khanna, MD, MS

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02161406

The ClinicalTrials.gov registry entry for NCT02161406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 90-participant average among 6 other Diffuse Cutaneous Systemic Sclerosis trials with a reported enrollment target. The listed sponsor is Dinesh Khanna, MD, MS, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Cutaneous Systemic Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02161406 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02161406 about?

NCT02161406 is a clinical study titled "A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis". The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score \[mRSS\]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.

What is the current status of trial NCT02161406?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2014-09. Estimated completion is 2018-10-17.

What conditions does trial NCT02161406 study?

This clinical trial studies the following conditions: Diffuse Cutaneous Systemic Sclerosis.

What interventions are being tested in trial NCT02161406?

The interventions under investigation include: Placebo (DRUG), Abatacept (DRUG).

Who is sponsoring clinical trial NCT02161406?

This trial is sponsored by Dinesh Khanna, MD, MS, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02161406 being conducted?

This trial has 20 study locations across California, District of Columbia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Cutaneous Systemic Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Cutaneous Systemic Sclerosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.